The enhanced energy production and metabolism of thyroid hormones, probably because of GSH replenishment provided by the L-glutamate portion of LOLA, opens a new therapeutic approach for MASLD. The gene discussed is TG; the disease is metabolic dysfunction-associated steatotic liver disease.